Neptra contains florfenicol, an antibiotic which Bayer says is ideal for dealing with the Staphylococcus pseudintermedius found in the majority of otitis externa cases, together with terbinafine hydrochloride, which is effective against Malassezia pachydermatis, and mometasone furoate, a corticosteroid that provides anti-inflammatory activity to improve patient comfort.
A single, 1ml dose in each affected ear treats dogs of all breeds and in trials, continuous clinical improvement was seen until day 28.
Neptra was approved for use in the USA back in 2015, where it has apparently gone down a bit of a storm, becoming the number one product for otitis externa in the country, with over 4.7 million doses prescribed since 2017.
Dr Ken Kwochka, DVM, DACVD, President of the World Association for Veterinary Dermatology (pictured right) said: "This solution is trusted by thousands of vets across the USA, it’s now time for UK vets to benefit from the convenience and confidence Neptra offers. Neptra is the ideal and easier way to treat the majority of otitis externa cases you see and can (and should) be used first-line."
Donna Tomlinson, Senior Brand Manager at Bayer said: "It’s not every day that you’re able to launch a solution that has the potential of Neptra to change treatment practices for the better and improve outcomes for dogs. Across the UK and Europe, our brilliant team at Bayer have put months of effort into this launch and developed an exciting marketing support package. Our veterinary business managers are already out on the road, ready to talk to you all about it."
Neptra is available now to order as one SKU via your regular wholesaler or speak to your Bayer veterinary business manager.
Practice support materials are also available via www.vetcentre.bayer.co.uk.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.